LLIVE: A non-interventional multicenter study of first-line Avastin® (bevacizumab) in combination with chemotherapy in patients with metastatic colorectal cancer in Lebanon

被引：0

作者：

Ali, Shamseddine ^{[1
]}

Sarah, Abdel Massih ^{[1
]}

George, Chahine ^{[2
]}

Fadi, Nasr ^{[3
]}

Joseph, Kattan ^{[4
]}

Fadi, Farhat ^{[5
]}

Bassim, Kobrossy ^{[6
]}

Dany, Abi Gerges ^{[7
]}

Walid, Moukadem ^{[8
]}

Chadi, Saba ^{[9
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Beirut, Lebanon

[2] Hotel Dieu de France, Beirut, Lebanon

[3] Mt Lebanon Hosp, Beirut, Lebanon

[4] St Joseph Hosp, Beirut, Lebanon

[5] Hammoud Hosp Univ, Med Ctr, Saida, Lebanon

[6] St George Hosp Univ, Med Ctr, Beirut, Lebanon

[7] Middle East Inst Hlth, Bsalim, Lebanon

[8] Haykal Hosp Tripoli, Tripoli, Lebanon

[9] Roche, Beirut, Lebanon

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-306

引用

页数：1

共 50 条

[21] A multicenter non-interventional study exploring the impact of sarcopenia on the outcomes of colorectal cancer patients treated with chemotherapy plus bevacizumab - avawatchers
Leen, Mortier
Pieter-Jan, Cuyle
Benedicte, Naessens
Koen, Hendrickx
Jochen, Decaestecker
Jan, Van de Vyver
Eric, Van Cutsem
ANNALS OF ONCOLOGY, 2017, 28
[22] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
Shaotang Li
Pan Dr Chi
BioDrugs, 2011, 25 : 43 - 50
[23] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
Bousahba, A.
Behourah, Z.
ANNALS OF ONCOLOGY, 2019, 30
[24] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
P García-Alfonso
A J Muñoz-Martin
S Alvarez-Suarez
Y Jerez-Gilarranz
M Riesco-Martinez
P Khosravi
M Martin
British Journal of Cancer, 2010, 103 : 1524 - 1528
[25] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
Garcia-Alfonso, P.
Munoz-Martin, A. J.
Alvarez-Suarez, S.
Jerez-Gilarranz, Y.
Riesco-Martinez, M.
Khosravi, P.
Martin, M.
BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1524 - 1528
[26] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
Qin, Shukui
Deng, Yanhong
Bi, Feng
Liu, Tian Shu
Liu, Yunpeng
Zhang, Suzhan
Xu, Jianming
Shu Yongqian
Xu, Nong
Wu, Changping
Wang, Xin
Zhong, Haijun
Feng, Jifeng
He, Yulong
Yang, Jianwei
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
Meyerhardt, Jeffrey A.
Li, Ling
Sanoff, Hanna K.
Carpenter, William
Schrag, Deborah
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 608 - 615
[28] Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial
Wang, Fenghua
Dai, Guanghai
Deng, Yanhong
Tang, Yong
Wang, Wei
Niu, Zuoxing
Bi, Feng
Zhu, Liangjun
Guo, Zengqing
Yan, Jin
Hu, Bing
Tao, Min
Yang, Shujun
Zhang, Suzhan
Wen, Lu
Xu, Ruihua
CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (04) : 490 - 499
[29] Bevacizumab (bev) combined with chemotherapy as first-line treatment in patients (pts) with advanced colorectal cancer: Final results from a large non-interventional community-based study
Hildebrandt, B.
Broszeit-Luft, S.
Bruch, H. R.
Zimber, J.
Hahn, L.
Lueck, A.
Kroening, H.
Tondar, S.
Kutscheidt, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S377 - S377
[30] Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
Vrdoljak, Eduard
Omrcen, Tomislav
Boban, Marijo
Hrabar, Andina
ANTI-CANCER DRUGS, 2011, 22 (02) : 191 - 197

← 1 2 3 4 5 →